This article has been cited by
1Targeting the ß2-integrin LFA-1, reduces adverse neuroimmune actions in neuropathic susceptibility caused by prenatal alcohol exposure
Joshua J. Sanchez,Jacob E. Sanchez,Shahani Noor,Chaselyn D. Ruffaner-Hanson,Suzy Davies,Carston R. Wagner,Lauren L. Jantzie,Nikolaos Mellios,Daniel D. Savage,Erin D. Milligan
Acta Neuropathologica Communications.2019;7(1)
[DOI]
2Reconsidering the central role of mucins in dry eye and ocular surface diseases
Christophe Baudouin,Maurizio Rolando,Jose M. Benitez Del Castillo,Elisabeth M. Messmer,Francisco C. Figueiredo,Murat Irkec,Gysbert Van Setten,Marc Labetoulle
Progress in Retinal and Eye Research.2019;71(1)68
[DOI]
3Reconsidering the central role of mucins in dry eye and ocular surface diseases
Caterina Sarnicola,Enrica Sarnicola,Paolo Perri,Vincenzo Sarnicola
Progress in Retinal and Eye Research.2020;71(1)35
[DOI]
4Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye
Kuei-Ju Cheng,Chien-Ming Hsieh,Kunal Nepali,Jing-Ping Liou
Journal of Medicinal Chemistry.2020;71(1)35
[DOI]
5Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease
Abhirup Mandal,Vrinda Gote,Dhananjay Pal,Abayomi Ogundele,Ashim K. Mitra
Pharmaceutical Research.2019;36(2)35
[DOI]
6Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease
Dorota Kopacz,Piotr Maciejewicz
Pharmaceutical Research.2019;36(2)35
[DOI]
7

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca

Gary W Jerkins,Guruprasad R Pattar,Shane R Kannarr
Clinical Ophthalmology.2020;Volume 14(2)481
[DOI]
8Current and Future Pharmacological Therapies for the Management of Dry Eye
Preeya K. Gupta,Penny Asbell,John Sheppard
Eye & Contact Lens: Science & Clinical Practice.2020;46(2)S64
[DOI]
9Neuropathic Corneal Pain
Gabriela Dieckmann,Sunali Goyal,Pedram Hamrah
Ophthalmology.2017;124(11)S34
[DOI]
10Synthetic Approaches to New Drugs Approved During 2016
Andrew C. Flick,Hong X. Ding,Carolyn A. Leverett,Sarah J. Fink,Christopher J. O’Donnell
Journal of Medicinal Chemistry.2018;61(16)7004
[DOI]
11The role of Th17 immunity in chronic ocular surface disorders
Nai-Wen Fan,Thomas H. Dohlman,William Foulsham,Matthew McSoley,Rohan Bir Singh,Yihe Chen,Reza Dana
The Ocular Surface.2020;61(16)7004
[DOI]
12An Efficient and Scalable Synthesis of Lifitegrast
Jayaprakash Rao Yerrabelly,Rajashekar Kommera,Venkateshwer Reddy Kasireddy,Venkat Reddy Ghojala,Hemasri Yerrabelly
ChemistrySelect.2020;5(11)3355
[DOI]
13Therapeutic inhibitors for the treatment of dry eye syndrome
Candela Rodríguez-Pomar,Jesus Pintor,Basilio Colligris,Gonzalo Carracedo
Expert Opinion on Pharmacotherapy.2017;18(17)1855
[DOI]
14Targets of immunomodulation in bacterial endophthalmitis
Frederick C. Miller,Phillip S. Coburn,Mursalin Md Huzzatul,Austin L. LaGrow,Erin Livingston,Michelle C. Callegan
Progress in Retinal and Eye Research.2019;73(17)100763
[DOI]
15Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA
José Antonio Encinar,Javier A. Menendez
Viruses.2020;12(5)525
[DOI]
16ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner
Wenzhi Shen,Xiaoyuan Zhang,Renle Du,Yan Fan,Dehong Luo,Yonghua Bao,Wancai Yang,Na Luo,Yunping Luo,Shuangtao Zhao
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2018;1864(8)2566
[DOI]
17Correlation of clinical symptoms and signs with conjunctival gene expression in primary Sjögren syndrome dry eye patients
H. Liang,K. Kessal,G. Rabut,P. Daull,J.S. Garrigue,S. Melik Parsadaniantz,M. Docquier,C. Baudouin,F. Brignole-Baudouin
The Ocular Surface.2019;17(3)516
[DOI]
18Impact of Attrition, Intercellular Shear in Dry Eye Disease: When Cells are Challenged and Neurons are Triggered
Gysbert-Botho van Setten
International Journal of Molecular Sciences.2020;21(12)4333
[DOI]
19The role of lipids in corneal diseases and dystrophies: a systematic review
Tyler G. Rowsey,Dimitrios Karamichos
Clinical and Translational Medicine.2017;6(1)4333
[DOI]
2030 Years of Biotherapeutics Development—What Have We Learned?
Nico Ghilardi,Rajita Pappu,Joseph R. Arron,Andrew C. Chan
Annual Review of Immunology.2020;38(1)249
[DOI]
  Feedback 
  Subscribe